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Abstract
Burkholderia pseudomallei, the etiologic agent of melioidosis, is endemic in northern Australia and Southeast Asia and can
cause severe septicemia that may lead to death in 20% to 50% of cases. Rapid detection of B. pseudomallei infection is
crucial for timely treatment of septic patients. This study evaluated seven commercially available DNA extraction kits to
determine the relative recovery of B. pseudomallei DNA from spiked EDTA-containing human whole blood. The evaluation
included three manual kits: the QIAamp DNA Mini kit, the QIAamp DNA Blood Mini kit, and the High Pure PCR Template
Preparation kit; and four automated systems: the MagNAPure LC using the DNA Isolation Kit I, the MagNAPure Compact
using the Nucleic Acid Isolation Kit I, and the QIAcube using the QIAamp DNA Mini kit and the QIAamp DNA Blood Mini kit.
Detection of B. pseudomallei DNA extracted by each kit was performed using the B. pseudomallei specific type III secretion
real-time PCR (TTS1) assay. Crossing threshold (CT) values were used to compare the limit of detection and reproducibility of
each kit. This study also compared the DNA concentrations and DNA purity yielded for each kit. The following kits
consistently yielded DNA that produced a detectable signal from blood spiked with 5.56104 colony forming units per mL:
the High Pure PCR Template Preparation, QIAamp DNA Mini, MagNA Pure Compact, and the QIAcube running the QIAamp
DNA Mini and QIAamp DNA Blood Mini kits. The High Pure PCR Template Preparation kit yielded the lowest limit of
detection with spiked blood, but when this kit was used with blood from patients with confirmed cases of melioidosis, the
bacteria was not reliably detected indicating blood may not be an optimal specimen.
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Introduction
Burkholderia pseudomallei, a Gram-negative bacterium, is the
etiologic agent of melioidosis; a disease with varying severity that
can affect both human and animal populations. B. pseudomallei is
recognized as a Select Agent by the Centers for Disease Control
and Prevention based on the criteria of infectivity, severity, and
environmental prevalence [1]. Melioidosis is endemic in Southeast
Asia and northern Australia but may occur in other tropical
regions of the world [2]. In its acute form, melioidosis can manifest
as a severe septicemia, which, without prompt diagnosis is often
fatal [3,4]. B. pseudomallei is resistant to many of the broad
spectrum antibiotics often used for treatment of sepsis [4]. Rapid
diagnosis of melioidosis allows for prompt treatment with
appropriate antibiotics and thus reduces mortality [4].
Culture of B. pseudomallei from any clinical specimen is the
current gold standard for the diagnosis of melioidosis. The
biochemical analysis may require up to seven days before
confirmation [5,6]. Serologic assays such as enzyme-linked
immunosorbent assays (ELISA) or indirect hemagglutination assay
(IHA) have been shown to be unreliable when used in regions
where melioidosis is endemic due to elevated antibody levels in
healthy populations [3,4,7,8]. Many polymerase chain reaction
(PCR) assays have been developed for the detection of B.
pseudomallei from a variety of sources such as clinical specimens,
environmental samples and pure culture by targeting a variety of
genes [9,10,11,12,13,14,15]. The ability to detect B. pseudomallei in
whole blood with PCR is dependent on the bacterial load, the
quantity and quality of the bacterial DNA extracted and the
elimination of PCR inhibitors.
There are many commercial DNA extraction kits that are
designed to extract quality DNA and eliminate PCR inhibitors
from blood samples. Many of these kits state their use is not
intended for clinical or diagnostic applications. However with
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proper verification, validation and quality control, they can be
valuable tools for the detection of pathogens with assays such as
conventional and real-time PCR, DNA sequencing, and DNA
hybridization assays. Commercial DNA extraction kits are
generally available worldwide, complete with standardized meth-
ods and reagents, and are simple to use [16].
No DNA extraction method has been shown to be optimal for
all bacteria [17]. There have been studies to determine the best
method for specific species of bacteria such as Brucella melitensis,
Mycobacterium spp., Leptospira spp., and most recently Bacillus anthracis
and Yersinia pestis [18,19,20,21,22]. A study by Merk et al. in 2006
used a B. pseudomallei surrogate organism, Burkholderia cepacia, to
compare DNA isolation methods for artificially infected ethylene-
diaminetetraacetic acid (EDTA)-containing equine blood and lung
tissue [23]. This study found that the High Pure PCR Template
Preparation kit performed the best. However, while our study is
similar, current Clinical and Laboratory Standards Institute
(CLSI) guidelines recommend evaluating performance standards
for each pathogen instead of using surrogate organisms. Ideally, as
part of the assessment process for determining sensitivity and
specificity, CLSI recommends using clinical specimens from
known cases of a given disease as part of the positive control
panel and using material from close relatives of a given pathogen
as part of the negative control panel [16].
The purpose of this study was to compare seven commercially
available DNA extraction kits to determine which may be best for
extracting B. pseudomallei genomic DNA from spiked whole blood
containing EDTA for detection by real-time PCR. The kits were
selected based on their availability in the United States of America,
Thailand, and Australia; varying throughput capacities; purifica-
tion technology and previous use by other laboratories for
detecting B. pseudomallei DNA. Kits were also selected based on
cost due to budget constraints that some laboratories may have.
Materials and Methods
Kit Selection
The DNA extraction formats tested include glass or silica filter
columns and magnetic bead automated systems which appear to
be the most common technologies used in commercial kits. These
kits also are considered less hazardous than older methods such as
the use of phenol/chloroform extractions which may expose staff
to carcinogens. Kits were also chosen based on both availability in
areas where melioidosis is endemic or where it poses a potential
biothreat concern. In addition some kits were not assessed based
on higher costs compared to those that were selected for
assessment. The following manual kits were evaluated: QIAamp
DNA Mini Kit (QIAamp Mini) (QIAGEN, Valencia, CA),
QIAamp DNA Blood Mini Kit (QIAamp Blood) (QIAGEN,
Valencia, CA), and the High Pure PCR Template Preparation Kit
(High Pure) (Roche Diagnostics, Indianapolis, IN). These kits were
compared with four automated systems which provide greater
throughput than manual kits: the MagNA Pure LC (Roche
Diagnostics, Indianapolis, IN) with the DNA Isolation Kit I
(MagNA LC) which can process 32 specimens per run, the
MagNA Pure Compact (Roche Diagnostics, Indianapolis, IN) with
the Nucleic Acid Isolation Kit I (MagNA Compact) which can
process eight specimens per run and the QIAcube (QIAGEN,
Valencia, CA) using both the QIAamp DNA Mini kit (QIAcube
Mini) and QIAamp DNA Blood Mini kit (QIAcube Blood) which
has a capacity of 12 specimens per run.
Bacterial Strains
The B. pseudomallei type strain, ATCC 23343, was used in this
study. All work done with B. pseudomallei live cultures was
performed in a biosafety level 3 (BSL-3) facility following BSL-3
safe practices and procedures.
Blood Spiking
Human whole blood for this experiment was obtained in
Vacutainer K2 EDTA tubes (BD Diagnostics, Sparks, MD) from
an anonymous donor through the Specimen Management Branch
of the CDC. B. pseudomallei bacteria were suspended in phosphate-
buffered saline (PBS) to between a 1 and 2 McFarland standard,
estimated to be 4.56108 colony forming units per milliliter (CFU/
mL). The whole blood with EDTA was spiked to 4.56107 CFU/
mL from this PBS solution for a 1:10 dilution, then serially diluted
in blood by 10-fold to a theoretical concentration of less than 1
CFU/mL. An aliquot of 100 ml from each dilution was plated on
trypticase soy agar containing 5% sheep blood (TSA II; BD
Diagnostics, Sparks, MD) in triplicate and incubated at 37uC for
48 hours for a more accurate enumeration than the estimate
yielded by using the McFarland standard. Due to the number of
kits tested and time constraints, all dilutions of the spiked blood
samples were stored frozen for each of the kits at 270uC. An
aliquot of a given dilution was thawed to room temperature just
prior to processing by a given kit.
DNA Extractions
The serial diluted spiked blood samples, as well as the negative
blood and negative water controls were extracted in triplicate
using seven different DNA extraction kits as follows. The two
manual QIAGEN kits tested in this study, the QIAamp Mini and
the QIAamp Blood, were used following the manufacturer’s
instructions for the blood and body fluid spin protocol. A 200 ml
blood sample was extracted, the optional spin at 20,0006g for
1 min prior to incubation and elution with Buffer AE was
performed, and 95% ethanol was used instead of the manufac-
turer’s recommended 96%–100% ethanol. A separate short study
indicated no significant difference in using 95% ethanol compared
to 99.5% ethanol (data not shown). Additionally, these two
QIAGEN kits were used with the QIAcube automated system
following the manufacturer’s instructions for sample setup of the
QIAcube Mini and QIAcube Blood kits. The High Pure kit was
used following the manufacturer’s instructions for 200 ml of
mammalian blood. The MagNA Compact utilized the Nucleic
Acid Isolation Kit I (Roche Applied Science, Indianapolis, IN),
which contains all necessary reagents and disposables. To optimize
DNA recovery and enhance cell deactivation, an optional external
lysis protocol was utilized prior to the automated MagNA
Compact extraction using the DNA Blood External Lysis
Purification protocol. This included combining 200 ml of the
blood sample with 300 ml of the MagNA Pure LC DNA Isolation
Kit I – Lysis/Binding Buffer, mixing, and incubating at room
temperature for 30 min. The MagNA LC utilized the MagNA
Pure LC DNA Isolation Kit I and the same external lysis was
completed, as described above, and DNA extracted using the
DNA Blood External Lysis Purification protocol, as described
above. The positive control, for the real-time PCR detection, was
a whole-cell lysate of B. pseudomallei (ATCC 23343) produced as
described previously by Hoffmaster et al. [24], which provided
crossing threshold (CT) values ranging between 23 and 28 cycles.
As a precaution all DNA extracts were filtered using 0.22-mm
centrifugal filter units (Millipore, Corporation, Billerica, MA) and
then an aliquot was plated to assess removal of viable cells. All
extracted DNA samples were stored at 220uC in their provided
Comparison DNA Kits B. pseudomallei Spiked Blood
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elution buffers, until analyzed by real-time PCR. Both water and
unspiked blood were processed alongside spiked blood and served
as extraction controls to determine if cross contamination
occurred.
Real-time PCR Detection
Detection of B. pseudomallei DNA in the extracted blood samples
was performed using the B. pseudomallei type III secretion system
(TTS1) real-time PCR assay with a SmartCycler II instrument
(Cepheid, Sunnyvale, CA) using the LightCycler FastStart DNA
Master HybProbe (Roche Diagnostics, Indianapolis, IN) PCR
master mix as previously described by Novak et al. [13]. The
following modifications were made to the TTS1 assay: 5 ml of
template was used in a final reaction volume of 25 ml and an
alteration of the cycling parameters was made to increase the
extension time from 15 s per cycle to 60 s per cycle.
Comparison of DNA Extraction Kits
The seven commercially available DNA extraction kits were
compared to determine their lower limit of detection. In order to
evaluate the recovery efficiency, each DNA extraction set was run
by the TTS1 real-time PCR assay in triplicate. This provided a
total of nine crossing threshold (CT) values, as determined by the
Smart Cycler DxH program (Cepheid, Sunnyvale, CA; Software
Version 1.7b), for each spiked blood dilution per extraction kit.
The CT values were used to determine the reproducibility of
results and the detection limit for each kit. The detection limit for
each DNA extraction kit was decided to be the lowest spiked blood
concentration at which 100% of the samples yielded positive
results. A 1 ml sample from each spiked blood DNA extraction
including the blood not spiked with bacteria was analyzed using
the NanoDrop ND-1000 spectrophotometer (Thermo Scientific,
Wilmington, DE, USA) in triplicate and the results averaged to
determine the DNA concentration, the absorbance at 260 nm
(A260), of the samples from each extraction kit. Additionally, the
absorbance at 280 nm (A280) was measured and the A260/A280
ratio determined to evaluate DNA purity. An average was taken
for all the samples extracted from each kit to determine the
average A260 value and A260/A280 ratio. To determine if PCR
inhibitors were being recovered along with DNA, DNA extracts of
non-spiked blood from the QIAamp Mini, QIAamp Blood, High
Pure, MagNA LC and MagNA Compact kits were mixed with
positive control DNA in a 10:1 ratio and tested for changes in CT
values compared to the positive control DNA combined with
H2O.
Testing on Clinical Blood Specimens
Eleven blood specimens from blood culture-confirmed cases of
melioidosis from Sa Kaeo and Nakhon Phanom Provinces,
Thailand were collected along with five blood specimens from
patients with E. coli septicemia as negative controls. Blood cultures
were collected at clinician discretion and were likely collected at
the time of admission. The blood specimens tested were collected
as part of a pneumonia study and patients were enrolled up to
24 hours after admission. The patients probably received antibi-
otics during the time between blood culture and collection of the
blood specimen tested as part of this evaluation. Specimens were
relabeled prior to processing so that the laboratorians were blinded
to origins of specimens and were processed using the Hi Pure kit
and tested using the TTS1 PCR assay. The blood specimens were
collected as part of a pneumonia etiology study approved by a
CDC Institutional Review Board and the Ethical Review
Committee of the Thailand Ministry of Public Health.
Statistical Analysis
To determine the reproducibility of the DNA extraction kits, we
analyzed experimental data from a balanced replicated design
with two factors, the type of extraction kits and the concentration,
using a two-way analysis of variance (ANOVA). This allowed us to
compare the effects of changing DNA extraction method and the
concentration on expected CT values. Pair-wise comparisons of CT
values for the DNA extraction kits were done using the Tukey
multiple comparisons test [25]. All analyses were performed using
the statistical software SAS 9.3 (SAS Institute, Cary, NC). All tests
of statistical significance were two-sided, and the significance level
was set at 5%.
Results
B. pseudomallei bacteria were used to generate serial dilutions of
spiked whole blood samples. By the plate count method the
concentrations of bacteria in the spiked samples ranged from
5.56106 CFU/mL down to an undetectable level. These serially
diluted samples were used for testing and comparison of the
performance of the seven DNA extraction kits.
The highest average DNA concentration was 51.55 ng/ml from
samples extracted by the QIAcube Blood, while the MagNA LC
extractions had the lowest DNA concentrations at an average of
4.90 ng/ml (Table 1). The MagNA Compact and the QIAcube
Mini had lower DNA concentrations of 16.37 ng/ml and
17.62 ng/ml, respectively, while the remaining kits had average
yields greater than 30 ng/ml. There was no observable correlation
in DNA concentration with the addition of bacteria, which is not
unexpected due to the relatively large mass of DNA provided by
human cells compared to the bacteria added (data not shown).
The QIAcube Mini, QIAcube Blood, and the MagNA Compact
extracted DNA samples had A260/A280 ratios that were between
1.7 and 1.9. The other DNA extraction kits all yielded samples
with A260/A280 ratios around 2.0 except for the MagNA LC, which
had a ratio of 2.25.
In this study, CT values using the TTS1 real-time PCR assay
were used to compare the limit of detection and reproducibility of
each kit. As shown in Table 2, the PCR limit of detection using
DNA extracted by the different kits varied 1000 fold, from
5.56103 to 5.56106 CFU/mL. The High Pure kit yielded DNA
extractions that resulted in the lowest limits of detection, 5.56103
CFU/mL at 100% of the time, and additionally was detected at
4.96102 CFU/mL at a frequency of roughly 11%. The QIAamp
Table 1. Average concentration and purity of DNA extraction
performed by commercially available DNA extraction kits on







QIAcube Blood 51.55 1.83
QIAamp Mini 38.05 2.06
QIAamp Blood 30.49 1.98
High Pure 30.01 2.07
QIAcube Mini 17.62 1.79
MagNA Compact 16.37 1.77
MagNA LC 4.90 2.25
Averages based on all blood specimens.
doi:10.1371/journal.pone.0058032.t001
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Mini, QIAcube Blood, QIAcube Mini, and the MagNA Compact
all yielded DNA preparations that were detected at various
frequencies at 5.56103 CFU/mL and 100% of the time from the
spiked blood samples at concentrations of 5.56104 CFU/mL and
greater. However, both the QIAamp Blood and the MagNA LC
had the higher limits of detection at 5.56105 CFU/mL, and
5.56106 CFU/mL, respectively.
The differences in the mean CT values for the seven DNA
extraction methods were found to be statistically significant by the
ANOVA test (P,0.05). The Tukey multiple comparison test
indicated that the High Pure kit was the DNA extraction kit that
yielded DNA providing CT values significantly lower than any of 6
other DNA extraction kits (P,0.05), after pairwise comparisons.
A test was performed using available DNA extracts from non-
spiked blood combined with positive control DNA. If inhibitors
were not removed, one would expect to see an increase in CT
values compared to the positive control DNA diluted with water.
No significant difference in CT values was observed (data not
shown). Extraction controls remained negative throughout the
study (data not shown).
Based on the performance of the High Pure kit with spiked
blood, we chose to evaluate it using 11 blood specimens from
patients in Thailand with confirmed cases of melioidosis. None
yielded amplification on all three of the triplicates using the TTS1
assay. However, one specimen indicated amplification on two of
the three triplicates. Three specimens had one of the triplicates
indicate amplification. CT values were at 40 or above. None of the
negative controls from the E. coli infections indicated amplification
(data not shown).
Discussion
B. pseudomallei infection can cause septicemia which is fatal in
roughly 50% of adult patients in Thailand, while the mortality rate
is about 20% in Australia [4,26]. Although broad spectrum
antimicrobial treatment is often initiated prior to bacterial
identification, B. pseudomallei infection, which can mimic other
infections, is resistant to treatment by many commonly used
antimicrobial agents [4]. Rapid diagnosis of infection could
expedite administration of appropriate antimicrobial therapy and
thereby potentially improve survival rates. Real-time PCR assays
have the capability to identify B. pseudomallei infection within hours.
Real-time PCR and other DNA-based methods for diagnosis are
dependent on the quality and timeliness of the DNA extraction
process.
Of the seven commercially available DNA extraction kits tested
in this study the High Pure kit yielded DNA extractions that
resulted in the lowest limits of detection, 5.56103 CFU/mL at
100% of the time, and additionally was detected at 4.96102 CFU/
mL at a frequency of roughly 11%. As a result of pairwise
comparisons, the High Pure kit was the DNA extraction kit
yielding the lowest CT values statistically (P,0.05).
If the Tukey multiple comparison test was run at three high
concentrations (5.56104, 5.56105 and 5.56106 CFU/mL), the
High Pure kit still had the lowest CT values statistically.
(P,0.05), as compared to six other DNA extraction kits
including QIAamp Blood. This indicates the consistently lowest
values for each of the diluted samples that were detected. The
QIAamp Mini, QIAamp Blood, MagNA Compact, QIAcube
Mini, and QIAcube Blood Mini kits yielded DNA extractions that
resulted in a limit of detection of 5.56104 CFU/mL, and
additionally were detected at 5.56103 CFU/mL at varying
frequencies.
The DNA concentrations determined by the Nanodrop ND-
1000 spectrophotometer indicate the total DNA extracted from
the whole blood specimen, which includes the bacterial DNA. The
majority of the DNA in the extracted samples is expected to be
from the whole blood itself due to the relatively large mass of blood
cells compared to the bacterial cells added. Thus it may not be
possible to predict detection of B. pseudomallei DNA based on the
DNA concentration, as the MagNA Compact had only 16.37 ng/
ml but had the same limit of detection as the manual QIAamp
Mini, which yielded 38.05 ng/ml. The DNA purity, A260/A280
ratio, was around 2.00 for the kits that performed best in this
study: the High Pure, QIAamp Mini, QIAcube Mini, QIAcube
Blood, and MagNA Compact. While there is no set standard for
what the optimal A260/A280 ratio is, it has generally been stated
that an A260/A280 ratio between 1.8 and 2.0 is considered to be
free of significant contamination [27].
The study done by Merk et al. in 2006 found that the High Pure
kit had the lowest limit of detection for EDTA equine blood that
was spiked with B. cepacia [23]. No other kits or DNA extraction
methods were assessed by their study and the current study. Merk
et al. determined the detection limit for the High Pure kit to be
between 2.66103 and 6.46104 CFU/mL, which is consistent with
our results indicating the detection limit to be 5.56103 CFU/mL.
There were a few differences in between these two studies; Merk
et al. centrifuged the whole blood samples and extracted DNA
from the pelleted samples and utilized conventional PCR [23].
Table 2. Comparison of seven DNA extraction kits based on the average crossing threshold (CT) values, standard deviation and
number of PCR positives using the TTS1 real-time PCR protocol.
B. pseudomallei CFU/mL 5.5610
6 5.56105 5.56104 5.56103 4.96102
Avg. CT (SD) # PCR+
Avg. CT
(SD) # PCR+ Avg. CT (SD) # PCR+
Avg. CT
(SD) # PCR+ Avg. CT (SD) # PCR+
High Pure 22.8 (0.4) 9/9 26.3 (0.7) 9/9 29.6 (0.6) 9/9 33.5 (0.4) 9/9 37.3 (0.0) 1/9
QIAamp Mini 24.8 (0.9) 9/9 27.3 (1.3) 9/9 30.0 (1.1) 9/9 35.9 (2.8) 7/9 2 0/9
QIAcube Blood 24.9 (0.8) 9/9 29.0 (0.6) 9/9 31.7 (0.4) 9/9 36.4 (1.1) 7/9 2 0/9
QIAcube Mini 25.4 (0.2) 9/9 29.4 (0.1) 9/9 32.9 (0.4) 9/9 38.3 (1.0) 5/9 2 0/9
MagNA Compact 26.1 (0.4) 9/9 28.9 (1.1) 9/9 32.6 (0.8) 9/9 34.8 (0.6) 2/9 2 0/9
QIAamp Blood 24.7 (1.1) 9/9 28.0 (0.7) 9/9 31.3 (1.0) 8/9 2 0/9 2 0/9
MagNA LC 29.1 (2.8) 9/9 33.8 (0.9) 8/9 34.8 (1.8) 4/9 2 0/9 2 0/9
CFU/mL = Colony forming units per milliliter; SD = Standard deviation.
doi:10.1371/journal.pone.0058032.t002
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The ability to extract sufficient B. pseudomallei DNA from whole
blood samples for detection by PCR would be an important
capacity for the rapid diagnosis and proper treatment of septic
melioidosis. This capacity would be most beneficial where B.
pseudomallei infection is endemic. In these regions the use of
commercial DNA extraction kits have many advantages including
the availability of the kits, ease of use, relative low cost and time
required, and standardization of the protocols and reagents.
Although the High Pure kit yielded the lowest limit of detection for
blood samples spiked with B. pseudomallei, other kits may offer other
advantages. For example, the other manual kits may have lower
associated costs for disposables and supplies. The High Pure kit
requires heating of the elution buffer which is not required by
some other manual kits such as the Qiagen kits. The other manual
Qiagen kits as well as the QIAcube Blood yielded higher total
DNA concentrations which may be advantageous if other PCR or
genetic testing will be performed for a given specimen. Manual kits
are labor intensive and are more prone to technician error, while
the automated kits take the same, if not more, time to perform a
single extraction, but require less time for set-up by laboratory
personnel and can increase throughput. However, testing of only
one or a few samples using automated systems may be costly and
wasteful. Manual kits are more flexible in the number of samples
that can be extracted, and samples can be tested individually upon
arrival in a time-sensitive scenario. The initial cost of setting up
automated systems is also more due to the need to purchase the
robot system to run the kits. However, automated systems would
result in relatively lower labor costs if large numbers of specimens
were to be processed.
A recent study in Thailand was done to better understand the
concentration of B. pseudomallei in different body fluids from
infected individuals. This study found that the median concentra-
tion of B. pseudomallei bacteria in blood from culture confirmed
cases is 1.1 CFU/mL and the greatest count was over 100 CFU/
mL [28]. Other studies have reported ranges from 1 to 1000
CFU/mL in septicemic patients’ blood [6,29,30]. Since the limit
of detection determined for the TTS1 real-time PCR with spiked
whole blood extracted using the High Pure kit was 5.56103 CFU/
mL, it may still be difficult to detect septic melioidosis by DNA
extraction and TTS1 real-time PCR. However, a small study on
clinical specimens with the TTS1 detection system was conducted
by Meumann et al. [31], who found that while the buffy coat from
blood samples extracted with the QIAamp DNA Mini Kit had
decreased sensitivity compared to other sample types tested, the
method was more successful than previous PCR methods. They
were able to detect B. pseudomallei in 56% of blood culture positive
samples and 17% of blood culture negative samples from patients
with confirmed melioidosis [31]. A more recent study by
Richardson et al. on clinical specimens from melioidosis patients
found that Qiagen QIAamp kits worked best using plasma.
Interestingly, they found that sputum and urine were the best
specimens. Their study did not include the Hi Pure kit [32]. It is
not possible to test all commercial kits available based on costs,
personnel constraints and limits of specimen availability. Labora-
tories that perform multiple tests on a given specimen may find
that the higher DNA yields of some kits such as the QIAcube
Blood may be advantageous compared to the Hi Pure kit. Also, the
higher throughput of the automated systems may be advantageous
compared to the manual labor required for the Hi Pure kit.
Our attempt to detect B. pseudomallei in blood specimens from
confirmed cases of melioidosis using the Hi Pure kit did not yield
amplification on all three of the triplicates for any of the culture
confirmed specimens tested even though this kit had the lowest
limit of detection on spiked blood. The failure could be due to low
levels of bacteria very near the threshold of the limit of detection
which may have been exacerbated by the start of antimicrobial
therapy prior to the blood draw. The timing of antimicrobial
therapy for these patients is not available.
As other studies have shown, PCR assays are highly specific
methods for detection but do need improvements in sensitivity
[33]. One strategy to improve the limit of detection of this assay
would be to centrifuge the whole blood samples and perform the
DNA extraction on the blood fraction that contains the
concentrated bacteria, as was done in the study by Merk et al.
[23], or performing the DNA extractions from a larger sample
volume. Testing of other specimen types such as sputum samples
and wound cultures have also shown significantly improved rates
of detection for B. pseudomallei as compared to blood samples [31].
Further studies, looking at a variety of clinical specimens from
patients with confirmed melioidosis is needed to see if these rapid
methods can significantly reduce the time for diagnosis. This study
illustrates the differences in performance of DNA extraction
methods as well as other variables to consider during molecular
assay development for the detection of specific pathogens. It also
further supports previous studies indicating the difficulty in
detecting B. pseudomallei in blood specimens.
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